Education
About Us
Working with TipRanks
Follow Us
InflaRx NV (IFRX)
NASDAQ:IFRX
IFRX Analyst Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IFRX Stock 12 Month Forecast
Average Price Target
$4.00
▲(233.33% Upside)
| Highest Price Target$6.00 | Average Price Target$4.00 | Lowest Price Target$2.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
―
Hold
―
Reiterated
10/24/25
InflaRx Hold Rating: Balancing Strategic Opportunities and Market UncertaintiesThis morning, Biogen announced a licensing deal with Vanqua Bio (private) for the exclusive worldwide rights of its preclinical, oral C5aR1 inhibitor. The terms of the agreement are as follows: $70M upfront, eligibility for up to $990M in potenal development, regulatory, commercial, and sales milestone payments, in addion to ered royales on potenal net sales. An IND filing for the C5aR1 inhibitor is expected in 2027. Notably, the Biogen PR said the following: "C5aR1 is a well-validated target involved in neutrophil-mediated inflammaon, which plays a central role across a range of inflammatory disorders." and "This agreement complements Biogen’s early-stage immunology pipeline by adding an oral mechanism with potenal applicability across mulple immune-mediated diseases." A few thoughts on this transacon as it relates to InflaRx and its oral C5aR1 inhibitor, INF904.
Leerink Partners
$2
Buy
66.67%
Upside
Reiterated
10/06/25
H.C. Wainwright
$6
Buy
400.00%
Upside
Reiterated
09/17/25
Raymond James
$13→$2
Buy
66.67%
Upside
Reiterated
05/29/25
Guggenheim
$10
Buy
733.33%
Upside
Reiterated
05/28/25
Oppenheimer
$6→$3
Buy
150.00%
Upside
Reiterated
05/28/25
Cantor Fitzgerald
$10
Buy
733.33%
Upside
Initiated
04/28/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
―
Hold
―
Reiterated
10/24/25
InflaRx Hold Rating: Balancing Strategic Opportunities and Market UncertaintiesThis morning, Biogen announced a licensing deal with Vanqua Bio (private) for the exclusive worldwide rights of its preclinical, oral C5aR1 inhibitor. The terms of the agreement are as follows: $70M upfront, eligibility for up to $990M in potenal development, regulatory, commercial, and sales milestone payments, in addion to ered royales on potenal net sales. An IND filing for the C5aR1 inhibitor is expected in 2027. Notably, the Biogen PR said the following: "C5aR1 is a well-validated target involved in neutrophil-mediated inflammaon, which plays a central role across a range of inflammatory disorders." and "This agreement complements Biogen’s early-stage immunology pipeline by adding an oral mechanism with potenal applicability across mulple immune-mediated diseases." A few thoughts on this transacon as it relates to InflaRx and its oral C5aR1 inhibitor, INF904.
Leerink Partners
$2
Buy
66.67%
Upside
Reiterated
10/06/25
H.C. Wainwright
$6
Buy
400.00%
Upside
Reiterated
09/17/25
Raymond James
$13→$2
Buy
66.67%
Upside
Reiterated
05/29/25
Guggenheim
$10
Buy
733.33%
Upside
Reiterated
05/28/25
Oppenheimer
$6→$3
Buy
150.00%
Upside
Reiterated
05/28/25
Cantor Fitzgerald
$10
Buy
733.33%
Upside
Initiated
04/28/25
Best Analysts Covering InflaRx
1 Month
xxx
Success Rate
7/19 ratings generated profit
Average Return
+5.32%
initiated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 36.84% of your transactions generating a profit, with an average return of +5.32% per trade.
3 Months
xxx
Success Rate
7/19 ratings generated profit
Average Return
+0.71%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 36.84% of your transactions generating a profit, with an average return of +0.71% per trade.
1 Year
Success Rate
5/19 ratings generated profit
Average Return
-17.95%
initiated a buy rating 6 months ago
Copying Steven Seedhouse's trades and holding each position for 1 Year would result in 26.32% of your transactions generating a profit, with an average return of -17.95% per trade.
2 Years
xxx
Success Rate
3/19 ratings generated profit
Average Return
-24.22%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 15.79% of your transactions generating a profit, with an average return of -24.22% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IFRX Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
8
8
3
3
2
Buy
0
0
0
1
1
Hold
7
11
11
15
11
Sell
3
3
2
2
1
Strong Sell
0
0
0
0
0
total
18
22
16
21
15
Each month's total comprises the sum of three months' worth of ratings.
IFRX Financial Forecast
IFRX Stock Forecast FAQ
What is IFRX’s average 12-month price target, according to analysts?
Based on analyst ratings, InflaRx NV’s 12-month average price target is 4.00.
What is IFRX’s upside potential, based on the analysts’ average price target?
InflaRx NV has 233.33% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IFRX a Buy, Sell or Hold?
InflaRx NV has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
What is InflaRx NV’s price target?
The average price target for InflaRx NV is 4.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $2.00. The average price target represents 233.33% Increase from the current price of $1.2.
The highest analyst price target is $6.00 ,the lowest forecast is $2.00. The average price target represents 233.33% Increase from the current price of $1.2.
What do analysts say about InflaRx NV?
InflaRx NV’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of IFRX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.